Beyond AFP (hepatocellular carcinoma), PSA (prostate cancer), and CA125 (ovarian cancer), which have relatively specific diagnostic value, other tumor markers must be comprehensively analyzed according to other clinical information from patients. This evidence concerns the gene AFP and ovarian carcinoma.